(20S)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
This invention discloses (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat immune disorders in humans as well as renal osteodystrophy.
1 - 28 . (canceled)
29 . A method of treating renal osteodystrophy comprising administering to a patient with renal osteodystrophy an effective amount of (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol having the formula:
30 . The method of claim 29 wherein (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered orally.
31 . The method of claim 29 wherein (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered parenterally.
32 . The method of claim 29 wherein (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered transdermally.
33 . The method of claim 29 wherein (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered in a dosage of from about 0.01 μg/day to about 100 μg/day.